Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) on Tuesday, soared 0.66% from the previous trading day, before settling in for the closing price of $464.51. Within the past 52 weeks, VRTX’s price has moved between $340.83 and $510.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.16% over the past five years. The company achieved an average annual earnings per share of -97.03%. With a float of $257.46 million, this company’s outstanding shares have now reached $257.70 million.
Let’s look at the performance matrix of the company that is accounted for 5400 employees.
Vertex Pharmaceuticals, Inc. (VRTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vertex Pharmaceuticals, Inc. is 0.25%, while institutional ownership is 92.81%. The most recent insider transaction that took place on Aug 08 ’24, was worth 602,447. Before that another transaction happened on Aug 08 ’24, when Company’s Director sold 1,292 for $466.29, making the entire transaction worth $602,447. This insider now owns 4,435 shares in total.
Vertex Pharmaceuticals, Inc. (VRTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -97.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.53% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Trading Performance Indicators
Vertex Pharmaceuticals, Inc. (VRTX) is currently performing well based on its current performance indicators. A quick ratio of 2.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.03, a number that is poised to hit 4.12 in the next quarter and is forecasted to reach 18.66 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc. (VRTX)
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) saw its 5-day average volume 1.19 million, a negative change from its year-to-date volume of 1.22 million. As of the previous 9 days, the stock’s Stochastic %D was 12.03%. Additionally, its Average True Range was 10.69.
During the past 100 days, Vertex Pharmaceuticals, Inc.’s (VRTX) raw stochastic average was set at 64.02%, which indicates a significant increase from 18.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.73% in the past 14 days, which was higher than the 17.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $481.30, while its 200-day Moving Average is $424.52. Nevertheless, the first resistance level for the watch stands at $471.89 in the near term. At $476.20, the stock is likely to face the second major resistance level. The third major resistance level sits at $483.12. If the price goes on to break the first support level at $460.66, it is likely to go to the next support level at $453.74. The third support level lies at $449.43 if the price breaches the second support level.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Key Stats
Market capitalization of the company is 120.68 billion based on 258,053K outstanding shares. Right now, sales total 9,869 M and income totals 3,620 M. The company made 2,646 M in profit during its latest quarter, and -3,594 M in sales during its previous quarter.
